RECRUITING

Type 1 Diabetes Extension Study

Description

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.

Study Overview

Study Details

Study overview

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.

Type 1 Diabetes Extension Study

Type 1 Diabetes Extension Study

Condition
Type 1 Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

San Francisco

UCSF School of Medicine, San Francisco, California, United States, 94143

Stanford

Stanford University, Stanford, California, United States, 94305

Aurora

University of Colorado School of Medicine: Barbara Davis Center for Diabetes, Aurora, Colorado, United States, 80045

New Haven

Yale University, New Haven, Connecticut, United States, 06519

Atlanta

Emory University, Atlanta, Georgia, United States, 30322

Indianapolis

Indiana University Riley Hospital for Children, Indianapolis, Indiana, United States, 46202

Iowa City

University of Iowa Health Care Division of Pediatric Endocrinology, Iowa City, Iowa, United States, 52242

Boston

Joslin Diabetes Center, Boston, Massachusetts, United States, 02215

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55454

Kansas City

Children's Mercy Hospital, Kansas City, Missouri, United States, 64108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
  • * Ability to sign informed consent/assent (as applicable for children).
  • * Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
  • * Inability to comply with the study visit schedule and required assessments.

Ages Eligible for Study

8 Years to 35 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

National Institute of Allergy and Infectious Diseases (NIAID),

Linda A. DiMeglio, MD, MPH,MA, STUDY_CHAIR, Riley Hospital for Children at Indiana University Health

Study Record Dates

2025-03